RESUMEN
Langerhans cell histiocytosis (LCH) is a disorder with a variety of clinical signs. The most severe forms affect risk organs (RO). The established role of the BRAF V600E mutation in LCH led to a targeted approach. However, targeted therapy cannot cure the disease, and cessation leads to quick relapses. Here, we combined cytosine-arabinoside (Ara-C) and 2'-chlorodeoxyadenosine (2-CdA) with targeted therapy to achieve stable remission. Nineteen children were enrolled in the study: 13 were RO-positive (RO+) and 6 RO-negative (RO-). Five patients received the therapy upfront, whereas the other 14 received it as a second or third line. The protocol starts with 28 days of vemurafenib (20 mg/kg), which is followed by 3 courses of Ara-C and 2-CdA (100 mg/m2 every 12 h, 6 mg/m2 per day, days 1-5) with concomitant vemurafenib therapy. After that, vemurafenib therapy was stopped, and 3 courses of mono 2-CdA followed. All patients rapidly responded to vemurafenib: the median disease activity score decreased from 13 to 2 points in the RO+ group and from 4.5 to 0 points in the RO- group on day 28. All patients except 1 received complete protocol treatment, and 15 of them did not have disease progression. The 2-year reactivation/progression-free survival (RFS) for RO+ was 76.9% with a median follow-up of 21 months and 83.3% with a median follow-up of 29 months for RO-. Overall survival is 100%. Importantly, 1 patient experienced secondary myelodysplastic syndrome after 14 months from vemurafenib cessation. Our study demonstrates that combined vemurafenib plus 2-CdA and Ara-C is effective in a cohort of children with LCH, and the toxicity is manageable. This trial is registered at www.clinicaltrials.gov as NCT03585686.
Asunto(s)
Cladribina , Histiocitosis de Células de Langerhans , Niño , Humanos , Cladribina/uso terapéutico , Vemurafenib/uso terapéutico , Proteínas Proto-Oncogénicas B-raf/genética , Citarabina/uso terapéutico , Recurrencia Local de Neoplasia/tratamiento farmacológico , Histiocitosis de Células de Langerhans/tratamiento farmacológico , Histiocitosis de Células de Langerhans/genéticaRESUMEN
In children (aged 3-8 years old) with minimal cerebral dysfunction the immune status was studied before and after cerebrolysin administration in the dosage of 1 ml per 10 kg of child's weight, intramuscularly, within one month. The cerebrolysin administration resulted in an increase in the level of CD19(+) cells with a simultaneous normalization of serum IgG and IgA levels. The count of CD4(+) lymphocytes has risen. Normalization of a relative count of CD16(+) cells (NK) was noted after cerebrolysin therapy. Expression of activation markers (CD25 and HLA DR) in total population of lymphocytes parallelly changed, achieving the parameters of the control group without any changes in expression of CD95 molecule. Under the cerebrolysin influence the activation mainly of T helpers could be observed in vitro.